GlassScriptPhysician profile
Warren C Wong
NPI 1881749240
$1,751.50
in general payments reported to CMS, 2019-2025
24 companies · $273 in 2025
The $273 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $179 · 2021: $317 · 2022: $135 · 2023: $213 · 2024: $344 · 2025: $273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $263.49 | 2020-2025 | Phesgo, Kadcyla, Perjeta |
| Janssen Biotech, INC. | $216.15 | 2021-2024 | Erleada |
| Janssen Pharmaceuticals, INC | $154.12 | 2020-2022 | |
| Incyte Corporation | $146.08 | 2019-2025 | Jakafi, Monjuvi |
| Global Blood Therapeutics, INC. | $117.92 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $111.97 | 2019-2020 | |
| Celgene Corporation | $76.44 | 2023-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $72.08 | 2019-2024 | Tagrisso, Calquence |
| Novartis Pharmaceuticals Corporation | $65.95 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $64.76 | 2020-2025 | |
| Astellas Pharma US INC | $60.10 | 2023-2024 | Padcev |
| Seagen INC. | $54.35 | 2020-2023 | Padcev, Tukysa |
| Pfizer INC. | $47.62 | 2024 | |
| Lilly USA, LLC | $45.85 | 2019-2024 | Verzenio |
| Merck Sharp & Dohme LLC | $36.64 | 2019-2024 | Keytruda |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmaessentia USA Corporation | $32.15 | 2024 | Besremi |
| Genzyme Corporation | $29.14 | 2021-2023 | |
| Daiichi Sankyo INC. | $28.73 | 2025 | Enhertu |
| Rigel Pharmaceuticals, INC. | $25.00 | 2019 | |
| Adaptive Biotechnologies Corporation | $23.39 | 2024 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $23.03 | 2025 | Onivyde |
| Gilead Sciences, INC. | $20.78 | 2025 | Trodelvy |
| Blueprint Medicines Corporation | $19.82 | 2025 | Ayvakit |
| Mirati Therapeutics, INC. | $15.94 | 2024 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.